{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:13:41Z","timestamp":1787670821010,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Transcatheter atrial septal defect (ASD) and patent foramen ovale (PFO) closure might have opposite short- and long-term haemodynamic consequences compared with restricted interatrial shunt creation, which recently emerged as a\u00a0potential treatment modality for patients with heart failure with preserved ejection fraction (HFpEF). Given the opposing approaches of ASD and PFO closure versus shunt creation, we investigated the early and sustained cardiac structural and functional changes following transcatheter ASD or PFO closure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective study, adult secundum-type ASD and PFO patients with complete echocardiography examinations at baseline and at 1\u2011day and 1\u2011year follow-up who also underwent transcatheter closure between 2013 and 2017\u202fat the University Medical Centre Groningen, the Netherlands were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-nine patients (mean age 48\u202f\u00b1\u2009standard deviation 16\u00a0years, 61.5% women) were included. Transcatheter ASD\/PFO closure resulted in an early and persistent decrease in right ventricular systolic and diastolic function. Additionally, transcatheter ASD\/PFO closure resulted in an early and sustained favourable response of left ventricular (LV) systolic function, but also in deterioration of LV diastolic function with an increase in LV filling pressure (LVFP), as assessed by echocardiography. Age (\u03b2\u202f=\u20090.31, <jats:italic>p<\/jats:italic>\u202f=\u20090.009) and atrial fibrillation (AF; \u03b2\u202f=\u20090.24, <jats:italic>p<\/jats:italic>\u202f=\u20090.03) were associated with a\u00a0sustained increase in LVFP after transcatheter ASD\/PFO closure estimated by mean E\/e\u2019 ratio (i.e. ratio of mitral peak velocity of early filling to diastolic mitral annular velocity). In subgroup analysis, this was similar for ASD and PFO closure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Older patients and patients with AF were predisposed to sustained increases in left-sided filling pressures resembling HFpEF following ASD or PFO closure. Consequently, these findings support the current concept that creating a\u00a0restricted interatrial shunt might be beneficial, particularly in elderly HFpEF patients with AF.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-021-01543-0","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T09:56:19Z","timestamp":1613728579000},"page":"402-408","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Short- and long-term haemodynamic consequences of transcatheter closure of atrial septal defect and patent foramen ovale"],"prefix":"10.1007","volume":"29","author":[{"given":"X.","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. M.","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. T.","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. F.","family":"Nauta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. S. S.","family":"Bamadhaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"van Melle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S. P.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. S.","family":"Hoendermis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"1543_CR1","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(13)62145-5","volume":"383","author":"T Geva","year":"2014","unstructured":"Geva\u00a0T, Martins\u00a0JD, Wald\u00a0RM. Atrial septal defects. Lancet. 2014;383:1921\u201332.","journal-title":"Lancet"},{"key":"1543_CR2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"Mas\u00a0JL, Derumeaux\u00a0G, Guillon\u00a0B, et\u00a0al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N\u00a0Engl J Med. 2017;377:1011\u201321.","journal-title":"N Engl J Med"},{"key":"1543_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.cardfail.2011.07.003","volume":"17","author":"S Masutani","year":"2011","unstructured":"Masutani\u00a0S, Senzaki\u00a0H. Left ventricular function in adult patients with atrial septal defect: implication for development of heart failure after transcatheter closure. J\u00a0Card Fail. 2011;17:957\u201363.","journal-title":"J Card Fail"},{"key":"1543_CR4","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.echo.2015.05.015","volume":"28","author":"FE Silvestry","year":"2015","unstructured":"Silvestry\u00a0FE, Cohen\u00a0MS, Armsby\u00a0LB, et\u00a0al. Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale: from the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. J\u00a0Am Soc Echocardiogr. 2015;28:910\u201358.","journal-title":"J Am Soc Echocardiogr"},{"key":"1543_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jcin.2009.12.011","volume":"3","author":"AA Khan","year":"2010","unstructured":"Khan\u00a0AA, Tan\u00a0JL, Li\u00a0W, et\u00a0al. The impact of transcatheter atrial septal defect closure in the older population. A prospective study. JACC Cardiovasc Interv. 2010;3:276\u201381.","journal-title":"JACC Cardiovasc Interv"},{"key":"1543_CR6","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/eurheartj\/ehx687","volume":"39","author":"C Nyboe","year":"2018","unstructured":"Nyboe\u00a0C, Karunanithi\u00a0Z, Nielsen-Kudsk\u00a0JE, et al. Long-term mortality in patients with atrial septal defect: a nationwide cohort-study. Eur Heart\u00a0J. 2018;39:993\u20138.","journal-title":"Eur Heart J"},{"key":"1543_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijcard.2017.03.073","volume":"241","author":"PA Villablanca","year":"2017","unstructured":"Villablanca\u00a0PA, Briston\u00a0DA, Rod\u00e9s-Cabau\u00a0J, et al. Treatment options for the closure of secundum atrial septal defects: a systematic review and meta-analysis. Int J Cardiol. 2017;241:149\u201355.","journal-title":"Int J Cardiol"},{"key":"1543_CR8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0140-6736(16)00704-2","volume":"387","author":"G Hasenfu\u00df","year":"2016","unstructured":"Hasenfu\u00df\u00a0G, Hayward\u00a0C, Burkhoff\u00a0D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387:1298\u2013304.","journal-title":"Lancet"},{"key":"1543_CR9","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/eurheartj\/ehq249","volume":"31","author":"H Baumgartner","year":"2010","unstructured":"Baumgartner\u00a0H, Bonhoeffer\u00a0P, De Groot\u00a0NMS, et al. ESC Guidelines for the management of grown-up congenital heart disease. Eur Heart\u00a0J. 2010;31:2915\u201357.","journal-title":"Eur Heart J"},{"key":"1543_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","volume":"16","author":"RM Lang","year":"2015","unstructured":"Lang\u00a0RM, Badano\u00a0LP, Mor-Avi\u00a0V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233\u201370.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1543_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/ccd.21075","volume":"69","author":"ET Wu","year":"2007","unstructured":"Wu\u00a0ET, Akagi\u00a0T, Taniguchi\u00a0M, et\u00a0al. Differences in right and left ventricular remodeling after transcatheter closure of atrial septal defect among adults. Catheter Cardiovasc Interv. 2007;69:866\u201371.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1543_CR12","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s10554-019-01647-0","volume":"35","author":"SS Stephensen","year":"2019","unstructured":"Stephensen\u00a0SS, Ostenfeld\u00a0E, Kutty\u00a0S, et al. Transcatheter closure of atrial septal defect in adults: time-course of atrial and ventricular remodeling and effects on exercise capacity. Int J Cardiovasc Imaging. 2019;35:2077\u201384.","journal-title":"Int J Cardiovasc Imaging"},{"key":"1543_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/hrt.2005.070060","volume":"92","author":"SP Schoen","year":"2006","unstructured":"Schoen\u00a0SP, Kittner\u00a0T, Bohl\u00a0S, et\u00a0al. Transcatheter closure of atrial septal defects improves right ventricular volume, mass, function, pulmonary pressure, and functional class: a magnetic resonance imaging study. Heart. 2006;92:821\u20136.","journal-title":"Heart"},{"key":"1543_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/ejechocard\/jen315","volume":"10","author":"SR Jategaonkar","year":"2009","unstructured":"Jategaonkar\u00a0SR, Scholtz\u00a0W, Butz\u00a0T, et al. Two-dimensional strain and strain rate imaging of the right ventricle in adult patients before and after percutaneous closure of atrial septal defects. Eur J Echocardiogr. 2009;10:499\u2013502.","journal-title":"Eur J Echocardiogr"},{"key":"1543_CR15","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam\u00a0CSP, Voors\u00a0AA, De Boer\u00a0RA, et\u00a0al. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart\u00a0J. 2018;39:2780\u201392.","journal-title":"Eur Heart J"},{"key":"1543_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ehf2.12350","volume":"6","author":"DM Kaye","year":"2019","unstructured":"Kaye\u00a0DM, Petrie\u00a0MC, McKenzie\u00a0S, et\u00a0al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail. 2019;6:62\u20139.","journal-title":"ESC Heart Fail"},{"key":"1543_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ejhf.111","volume":"16","author":"L S\u00f8ndergaard","year":"2014","unstructured":"S\u00f8ndergaard\u00a0L, Reddy\u00a0V, Kaye\u00a0D, et\u00a0al. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a\u00a0novel interatrial implant to lower left atrial pressure. Eur J Heart Fail. 2014;16:796\u2013801.","journal-title":"Eur J Heart Fail"},{"key":"1543_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.cardfail.2015.05.008","volume":"21","author":"G Hasenfuss","year":"2015","unstructured":"Hasenfuss\u00a0G, Gustafsson\u00a0F, Kaye\u00a0D, et al. Rationale and design of the reduce elevated left atrial pressure in patients with heart failure (reduce LAP-HF) trial. J\u00a0Card Fail. 2015;21:594\u2013600.","journal-title":"J Card Fail"},{"key":"1543_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.117.032094","volume":"137","author":"T Feldman","year":"2018","unstructured":"Feldman\u00a0T, Mauri\u00a0L, Kahwash\u00a0R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF i [reduce elevated left atrial pressure in patients with heart failure]): a phase 2, randomized, sham-controlled trial. Circulation. 2018;137:364\u201375.","journal-title":"Circulation"},{"key":"1543_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2018.2936","volume":"3","author":"SJ Shah","year":"2018","unstructured":"Shah\u00a0SJ, Feldman\u00a0T, Ricciardi\u00a0MJ, et al. One-year safety and clinical outcomes of a\u00a0transcatheter Interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol. 2018;3:968\u201377.","journal-title":"JAMA Cardiol"},{"key":"1543_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/1522-726X(200102)52:2<177::AID-CCD1043>3.0.CO;2-G","volume":"52","author":"P Ewert","year":"2001","unstructured":"Ewert\u00a0P, Berger\u00a0F, Nagdyman\u00a0N, et\u00a0al. Masked left ventricular restriction in elderly patients with atrial septal defects: a contraindication for closure? Catheter Cardiovasc Interv. 2001;52:177\u201380.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1543_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ccd.20292","volume":"64","author":"S Schubert","year":"2005","unstructured":"Schubert\u00a0S, Peters\u00a0B, Abdul-Khaliq\u00a0H, et al. Left ventricular conditioning in the elderly patient to prevent congestive heart failure after transcatheter closure of atrial septal defect. Catheter Cardiovasc Interv. 2005;64:333\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1543_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/ejhf.1220","volume":"20","author":"JF Nauta","year":"2018","unstructured":"Nauta\u00a0JF, Hummel\u00a0YM, van der Meer\u00a0P, et\u00a0al. Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE\/EACVI recommendations: a\u00a0systematic review in patients with preserved ejection fraction. Eur J Heart Fail. 2018;20:1303\u201311.","journal-title":"Eur J Heart Fail"},{"key":"1543_CR24","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.jacc.2017.01.058","volume":"69","author":"OS Andersen","year":"2017","unstructured":"Andersen\u00a0OS, Smiseth\u00a0OA, Dokainish\u00a0H, et\u00a0al. Estimating left ventricular filling pressure by\u00a0echocardiography. J\u00a0Am Coll Cardiol. 2017;69:1937\u201348.","journal-title":"J Am Coll Cardiol"},{"key":"1543_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.1464","volume":"21","author":"YNV Reddy","year":"2019","unstructured":"Reddy\u00a0YNV, Obokata\u00a0M, Egbe\u00a0A, et\u00a0al. Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. Eur J Heart Fail. 2019;21:891\u2013900.","journal-title":"Eur J Heart Fail"},{"key":"1543_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00380-011-0122-8","volume":"27","author":"SMS Masutani","year":"2012","unstructured":"Masutani\u00a0SMS, Taketazu\u00a0M, Ishido\u00a0H, et\u00a0al. Effects of age on hemodynamic changes after transcatheter closure of atrial septal defect: importance of ventricular diastolic function. Heart Vessels. 2012;27:71\u20138.","journal-title":"Heart Vessels"},{"key":"1543_CR27","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ijcard.2012.04.081","volume":"167","author":"O Monfredi","year":"2013","unstructured":"Monfredi\u00a0O, Luckie\u00a0M, Mirjafari\u00a0H, et\u00a0al. Percutaneous device closure of atrial septal defect results in very early and sustained changes of right and left heart function. Int J Cardiol. 2013;167:1578\u201384.","journal-title":"Int J Cardiol"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01543-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-021-01543-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01543-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T14:34:07Z","timestamp":1625841247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-021-01543-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":27,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s12471-021-01543-0","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"25 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.S.P. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board\/Steering Committee\/Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cytokinetics, Darma Inc., Us2.ai, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Stealth BioTherapeutics, The Corpus, Vifor Pharma and WebMD Global LLC; and serves as co-founder & non-executive director of Us2.ai. X.\u00a0Jin, Y.M.\u00a0Hummel, W.T.\u00a0Tay, J.F.\u00a0Nauta, N.S.S.\u00a0Bamadhaj, J.P.\u00a0van Melle, A.A.\u00a0Voors and E.S.\u00a0Hoendermis declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}